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Abstract 
Fear learning deficiencies might contribute to the development and maintenance of chronic 
pain disability. Fear is often not restricted to movements (conditioned stimulus=CS+) originally 
associated with pain (unconditioned stimulus=US), but expands to similar movements (generalization 
stimuli=GSs). This spreading of fear becomes dysfunctional when overgeneralization to safe stimuli 
occurs. More importantly, persistence of pain-related fear to GSs despite corrective feedback might 
even be more debilitating and maintain long-term chronic pain disability. Yet, research on this topic is 
lacking.  
Using a voluntary joystick movement paradigm, we examined (extinction of) pain-related fear 
generalization in fibromyalgia patients (FM) and healthy controls (HC). During acquisition, one 
movement (CS+) predicted pain; another did not (CS-). We tested (extinction of) fear generalization to 
five GSs varying in similarity with the CS+ and CS-. Results revealed flatter pain-expectancy 
generalization gradients in FM than HC due to elevated responses to GSs more similar to the CS-; the 
fear generalization gradients did not differ. Although, pain-related fear and expectancy to the GSs 
decreased during extinction, responding to the GSs remained higher for FM than HC, suggesting that 
extinction of generalization is impaired in chronic pain patients. Persistence of excessive protective 
responses may contribute to maintaining long-term chronic pain disability. 
Perspective: Pain-related fear and expectancy to movements –varying in similarity with the 
original painful and non-painful movement– decrease during extinction in healthy controls and 
fibromyalgia patients. Yet, conditioned responses remain elevated in patients despite corrective 
feedback, indicating impaired extinction of generalization. Persistent excessive protective responses 
may contribute to preserving pain disability. 
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1. Introduction  
Accumulating evidence indicates that pain-related fear plays a fundamental role in the transition 
from acute to chronic disabling pain59. Fear can be defined as an (phasic) emotional response to the 
anticipation or imminence of threat, harm, or in the specific case of pain-related fear, pain. It is 
commonly accepted that fear can at least be expressed in three response systems24: (1) verbal 
responding (both cognition and affect), (2) psychophysiological responding (changes in autonomic 
responding and reflex modulation), and (3) behavioral changes (such as avoidance or removal from 
the source of threat). It has been shown repeatedly that pain-related fear can be acquired via 
associative learning31-38, 52. An initially neutral movement (conditioned stimulus=CS+) that is 
associated with pain (unconditioned stimulus=pain-US) starts to signal danger and evokes protective 
behavior (conditioned responses=CR), while the CS- (control stimulus never paired with the pain-US) 
does not trigger such responses. Fear learning is an adaptive mechanism, because the ability to identify 
cues signaling threat and safety enables protective action against potential bodily harm. In the clinic, 
however, spreading of fear and avoidance is observed beyond movements/activities that were 
associated with pain during the original pain episode. For example, when someone experiences a 
shooting back pain while lifting a box, it is possible (s)he will not only expect to feel pain and be 
fearful to lift this specific box, but also when lifting other objects (e.g. a baby, a shopping bag). One 
possible mechanism accounting for this spreading of fear is stimulus generalization14, 19, 22. Stimulus 
generalization is also adaptive as it enables individuals to extrapolate the predictive value of one 
stimulus to novel, similar stimuli without actually having to experience them. From an associative 
learning perspective this implies that CRs may extend to a range of novel stimuli resembling the 
original CS+, with more similar GSs evoking stronger CRs. Yet, together with reducing the risk of 
missing positive threat alarms, which may contribute to avoiding harm in a swiftly changing 
environment, generalization bears an increased risk to respond to false threat alarms. In particular, 
when fear spreads in an unbridled way, stimulus generalization becomes maladaptive and may lead to 
dysfunctional protective behaviors and culminate in severe pain disability.  
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In a previous study, we demonstrated that fear indeed spreads selectively towards novel 
movements resembling the original painful movement in healthy pain-free controls (HC), but fear 
generalized in a non-differential way in fibromyalgia patients (FM)31. In another study using a 
scenario contingency learning task with the verbal labels ‘pain’ and ‘no pain’ as outcomes and pictures 
of hand postures as cues, we found that chronic hand pain patients overgeneralized pain-outcome 
expectancy to novel cues that were more similar to the original ‘safe’ cue as compared to HC30. We 
argued that excessive generalization might be involved in the etiology of chronic pain disability by 
spreading of undesired protective behaviors. Moreover, persistence of pain-related fear and 
expectancy to technically safe, unreinforced GSs despite corrective feedback might even be more 
debilitating and maintain chronic pain disability in the long run, however to our knowledge this has 
never been tested. Therefore, this study aimed to test pain-related fear generalization and its extinction 
in FM and HC using a voluntary joystick movement conditioning task. We hypothesized that FM 
would show 1) flatter generalization gradients than HC due to higher responses to the GSs that 
resemble the original CS- more, 2) impaired extinction of unreinforced GSs, whereas generalized 
pain-related fear will subside quickly in HC.  
2. Methods and Materials 
2.1. Participants 
This study used a convenience sample of 60 participants including two age-matched diagnostic 
groups: 30 fibromyalgia patients (29 females, mean ± SD (range) age = 41 ± 11 (22–59) years), and 30 
healthy controls (mean ± SD (range) age = 41 ± 12 (21–60) years). In line with Meulders et al.31, we 
chose not to use absolute age-matched groups, but used 5-year ranges to match the healthy controls 
(HC) to the fibromyalgia (FM) group. The most important inclusion criterion for the FM group was to 
be diagnosed with fibromyalgia and experiencing some interference in their daily life because of this 
condition. All patients satisfied the American College of Rheumatology (ACR) new diagnostic criteria 
for fibromyalgia58 based on the combined Widespread Pain Index (WPI; range 0-19) and Symptom 
Severity Score (SS; range 0-12) (see Table 1). The inclusion criterion for the HC group was to not 
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have fibromyalgia. Exclusion criteria for both groups were: any other chronic pain conditions, 
diagnosed dyslexia or analphabetism, pregnancy, current or history of cardiovascular disease, chronic 
or acute respiratory disease (e.g., asthma, bronchitis), neurological diseases (e.g., epilepsy), 
uncorrected hearing problems, having pain at the dominant hand, wrist or arm that hinders to move a 
joystick painlessly, cardiac pacemaker or the presence of any other electronic medical devices, and the 
presence of any other severe medical conditions. An additional exclusion criterion only for the HC 
group was: any current or past psychiatric disorder including clinical depression and panic/anxiety 
disorder. Because of its high comorbidity with depression, other mood disorders and anxiety23, 48, 55 
this additional criterion was omitted in the FM group. Participants were recruited via social media and 
from pain clinics in the Limburg region (Belgium). The study protocol was approved by the Social and 
Societal Ethics Committee of the KU Leuven (registration number: S-56226), the Medical Ethical 
Committee of Ziekenhuis Oost-Limburg (ZOL), and the Medical Ethical Committee of the University 
Hospital of KU Leuven (ML10116). All participants signed the informed consent form, which 
explicitly stated that they were allowed to decline participation at any time during the experiment. To 
compensate for their time and effort, FM patients received the book ‘Mastering your Pain’ [de Pijn de 
Baas] by Frits Winter57, HC received a box of Belgian chocolates; both remunerations had an 
approximate value of €15. As expected, FM patients had lower educational level, were more likely to 
be unemployed, and were taking more medication than the healthy controls. More detailed 
demographic and clinical characteristics can be found in Table 1. 
2.2.Stimulus material and apparatus 
The experiment was run on a Windows 7 computer (Dell OptiPlex 7010) with 4096MB RAM and 
an Intel Core i5-3570 CPU processor at 3.40 GHz and an AMD Radeon HD 7570 graphics card with 
2542MB of video RAM. Experimental stimuli were presented on a 19-inch computer screen and were 
controlled with the free experimental software package Affect 4.047. The data were stored using a 
National Instruments data acquisition card (National Instruments Corporation, Austin, Texas). The 
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conditioned stimuli (CSs) and the generalization stimuli (GSs) were seven, equally spaced movement 
quadrants, which are part of a semi-circle (see Figure 1). These proprioceptive stimuli consisted of 
moving a Paccus Hawk joystick (Paccus Interfaces BV, Almere, The Netherlands) with the dominant 
hand within one of the seven movement quadrants. Movements in quadrant 1 (i.e. 90° to the left) and 
in quadrant 7 (i.e. 90° to the right) served as CSs, and movements in the intermediate (2-6) quadrants, 
served as GSs. During acquisition, one movement direction (CS+) was followed by the pain-US (75% 
of the trials), while the other movement direction was never followed by the pain-US (CS-); which 
movement quadrant (1 or 7) served as CS+ or CS- was counterbalanced across participants. The pain-
US was a painful electrocutaneous stimulus (2 ms duration), generated by a commercial constant 
current stimulator (DS7A, Digitimer) and administered through surface Sensor Medics electrodes 
(8mm) filled with K-Y gel that were attached to the wrist of the dominant hand. Before the experiment 
started, participants went through a calibration procedure: they received a series of electrocutaneous 
stimuli of increasing intensity and were asked to indicate how intense each stimulus was on a scale 
from 1 to 10 where ‘1’ means: “you feel something but this is not painful, it is merely a sensation”; ‘2’ 
means: “this sensation starts to be painful, but it is still a very moderate pain” up to ‘10’ which means: 
“this is the worst pain you can imagine”. A subjective stimulus intensity of ‘8’ which refers to a 
stimulus that is “significantly painful and demanding some effort to tolerate” was targeted. The mean 
self-reported stimulus intensity was 7.87 (SD = 0.35, range = 7–8) for the FM group, and 7.98 (SD = 
0.18, range = 7–8) for the HC group. The mean physical stimulus intensity (in mA) was 18.73 (SD = 
8.53, range = 8–48) for the FM group, and 22.90 (SD = 12.18, range = 11–60) for the HC group. 
Conditioned pain-related fear was assessed through self-reports as well as a psychophysiological 
index of fear learning, that is, the eyeblink startle response. The eyeblink startle response is a 
component of the reflexive cross-species, full-body defensive response mobilization, which is 
triggered by startle-evoking stimuli (e.g., acoustic startle probe) and can be measured by the tension in 
the muscles underneath the eye. Startle modulation refers to the potentiation of the startle reflex during 
fear states elicited by the anticipation of an aversive stimulus (e.g., an electrocutaneous stimulus). In 
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the present setup, the startle probe was a 100 dBA burst of white noise with instantaneous rise time 
presented binaurally for 50 ms through headphones (Philips SHP2500). Eyeblink startle responses 
elicited by startle probes delivered during the CS/GS movements served as an index of cued pain-
related fear. Eyeblink startle responses elicited by startle probes during the intertrial interval (ITI) 
served as an index of contextual pain-related fear. 
2.3. Experimental setting 
Participants were seated in an armchair (0.6 m screen distance) in a sound-attenuated and 
dimmed experimental room, adjacent to the experimenter's room. Further verbal communication was 
possible through an intercom system; the experimenter observed the participants and their 
physiological responses online by means of a closed-circuit TV installation and computer monitors.  
2.4. Procedure	
The experiment was conducted during a 2-hour session and comprised six experimental 
phases: a preparation phase, a practice phase, a habituation phase, an acquisition phase, a transfer-of-
acquisition phase, and a generalization phase. The procedure is largely based on Meulders et al. 33. In a 
mixed design (see Table 2) participants in both groups (between-subjects factor: FM vs. HC) received 
a pain-US after moving the joystick to the CS+ direction on 75% of the trials, but never received a 
pain-US when moving the joystick to the CS- direction (within-subjects factor: CS+ vs. CS-). Note 
that the movement direction that served as the CS+ and CS- was counterbalanced across participants. 
During acquisition, participants freely chose on each trial in which direction they were going to move 
the joystick. During the transfer-of-acquisition, however, they could no longer choose the order of the 
movements themselves, but the movement direction was “signaled”. During generalization, the same 
signaling procedure was used to test the spreading of conditioned fear to novel intermediate movement 
directions (GSs). 
2.4. 1. Preparation phase 
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Upon arrival to the laboratory, participants were informed that pain-USs and short loud noises 
(acoustic startle probes) would be administered during the experiment. Participants were also told that 
they were free to decline participation at any time without any consequences. Subsequently, written 
informed consent was obtained. Before selecting the intensity of the painful stimulus following the 
calibration procedure, electrodes for the eyeblink startle responses and the electrocutaneous stimulus 
were attached  (see ‘2.2. Stimulus material and apparatus’ section).  
2.4.2. Practice  
Figure 1 provides an illustrative overview of the design and the voluntary joystick movement 
task. Before starting the practice phase, participants received detailed instructions about the 
experimental task. At the beginning of each trial the cursor representing the joystick needed to be 
positioned in the middle of the screen, so that the joystick was standing upright and centered. When 
prompted by a starting signal “+” (fixation cross presented in the middle of the computer screen), 
participants moved the joystick as quickly and accurately as possible, in whatever order they freely 
chose. They were requested to move the joystick towards the counter bars, each divided in four equal 
segments, positioned at the end of the two equally spaced movement quadrants (1 and 7). Successful 
movements always resulted in coloring one segment of the corresponding counter bar blue. That way, 
participants could instantly ascertain how many movements in each direction still were to be 
performed. During this phase, visual feedback about the position of the joystick (i.e. visualized by the 
cursor) and the performance of the movements was provided on the computer screen. The movement 
quadrants were delineated with white borders. Whenever the cursor (representing the joystick 
position) entered a quadrant, this area turned green. When the cursor wrongly left the movement 
quadrant, this area turned red. During the practice phase participants completed 16 valid movements, 
that is, two blocks of eight trials (4left/4right) in total. No pain-USs or startle probes were presented 
during this phase, but the experimenter provided verbal feedback about the performance of the 
joystick movements.  
2.4.3. Startle habituation 
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Because the first responses to the startle probes are usually relatively large, we included a 
phase to habituate to the probes, to correct for such possible confounds during the data collection. This 
habituation phase consisted of 8 trials, each lasting 12s, with an intertrial interval (ITI) of 2s. During 
each trial one startle probe (100 dBA burst of white noise) was delivered between the 8th and the 12th 
second after trial onset. Participants wore headphones, and the lights in the experimental room were 
dimmed. No pain-USs were delivered during this phase. 
2.4.4. Acquisition 
This phase was basically the same as the practice phase (see Figure 1), but now 1) no verbal 
feedback was administered about the task performance, 2) pain-USs and startle probes were presented, 
3) the movement quadrants were not delineated with white borders and they did not turn green/red 
when the cursor entered/left the corresponding movement quadrant; the cursor was no longer visible 
for the participant, 4) instructions emphasized to pay close attention to the starting signal “+” and to 
respond as fast and accurately as possible upon its presentation.  
The acquisition phase consisted of three blocks of 8 trials. Each block contained 4 trials to the 
left and 4 trials to the right. Although a CS movement was of variable length depending on the 
participants’ movement speed, a trial typically included an ITI consisting of a pre-CS-interval of 3 s 
and a post-CS-interval of 8 s. The pain-US was presented on 75% of the CS+ trials, but never on CS- 
trials. In each block of eight CS movements, four of the startle probes were presented during the CS 
movements, and four during the ITI (between 3000 – 6000 ms after the movement was executed). 
Note that we did not inform the participants about the contingencies between the joystick movements 
(CSs) and the pain-US. After each conditioning block, participants rated the pain-related fear elicited 
by each of the CS movements.  
2.4.5. Transfer-of-acquisition 
Transfer of acquisition trials were identical as those during the acquisition phase, with the 
exception that participants could no longer freely choose in which order they performed the CS 
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movements. More specifically, 3000 ms after trial onset, a green border was presented around the 
counter bars of one of the movement quadrants to indicate in which direction participants were to 
move. Before actually performing the movement, participants rated to what extent they expected to 
receive a pain-US after the to-be-performed movement, and to what extent they were afraid to perform 
that movement. After answering these questions, participants waited for the starting signal to appear 
and started moving into the signaled direction. After successfully performing the signaled CS 
movement, a post-CS-ITI of 8 s followed. During the transfer phase, one block of eight trials 
(4left/4right) was run. The reinforcement scheme and timing scheme of the presentation of the startle 
probes remained the same as during the acquisition phase. 
2.4.6.Generalization  
The procedure of the generalization phase was mainly the same as the transfer-of-acquisition 
phase. The difference was that participants now had to perform five novel movements (GSs) into 
intermediate movement quadrants (2-6) between the CS+ and the CS-. Movements to quadrant 1 or 7 
still served as CS+ and remained reinforced at the same rate; the CS- and GSs, however, were never 
followed by the pain-US. The generalization phase consisted of 28 trials, in which participants 
performed 4 trials of each movement (i.e., quadrants 1-7). One block consists of 7 movements (one in 
each movement quadrant); the order of the movements was randomized across participants. As before, 
after a 3s pre-CS/GS ITI, the movement direction was signaled by a green border around the counter 
bar of the corresponding movement quadrant and participants rated their pain-US expectancy and 
pain-related fear. Next, the fixation cross appeared and participants moved the joystick into the 
signaled direction. After successfully performing the movement, again a post-CS/GS ITI of 8 s 
followed. On each trial a startle probe was delivered during the GS/CS movement; no ITI probes were 
delivered.  
2.5. Measures 
2.5.1. Manipulation checks  
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Affective valence, arousal and control. After the practice, acquisition and generalization 
phase, participants completed three Self-Assessment Manikin (SAM) scales4 measuring affective 
valence, arousal and the control they experienced when performing the CS movements. The SAM 
scales each consisted of 5 different pictographs of humanlike figures – manikins. These manikins 
differ in emotional expressions ranging respectively from “happy” to “unhappy”, “very aroused” to 
“calm”, “no control” to “a lot of control”. Participants selected the manikin that matched best how 
they felt when performing the respective CS movements. Responses were scored from 1 to 5 
(happy/very aroused/no control– sad/calm/a lot of control).  
2.5.2. Main outcome variables 
Self-reported fear of movement-related pain. After each block, participants answered the 
following question: “How afraid were you to perform the left/right movement?” on an 11-point Likert 
scale ranging from 0 to 10 with anchors ‘not fearful at all’ to ‘extremely fearful’. During the transfer 
of acquisition and the generalization phases, participants rated before each movement how afraid they 
were to actually perform the signaled movements (CSs/GSs).  
Pain-US expectancy during transfer-of-acquisition and generalization. During the transfer-of-
acquisition and generalization phases, participants rated before each movement to what extent they 
expected the painful stimulus to occur when performing the signaled movements (CSs/GSs) on an 11-
point Likert scale (range 0-10) with labels ‘not at all’ to ‘very much’.  
Eyeblink startle modulation. Orbicularis Oculi electromyographic activity (EMG) was 
recorded with three Ag/AgCl Sensormedics electrodes (4 mm) filled with electrolyte gel. After 
cleaning the skin with exfoliating peeling cream to reduce inter-electrode resistance, electrodes were 
placed on the left side of the face according to the site specifications proposed by Blumenthal et al. 2. 
The raw signal was amplified by a Coulbourn isolated bioamplifier with bandpass filter (LabLinc v75–
04). The recording bandwidth of the EMG signal was between 90 Hz and 1 kHz (±3 dB). The signal 
was rectified online and smoothed by a Coulbourn multifunction integrator (LabLinc v76–23 A) with 
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a time constant of 20 ms. The EMG signal was digitized at 1000 Hz from 200 ms before the onset of 
the auditory startle probe until 1000 ms after probe onset. 
Pain-US intensity and unpleasantness. After each block, participants indicated the 
unpleasantness and the intensity of the painful stimulus on an 11-point Likert scale (range 0-10) with 
labels “not unpleasant at all” and “very unpleasant”, and “not painful at all” and “very painful”. 
2.5.3 Post-experimental questionnaires 
After the data collection, all participants completed a battery of questionnaires to map out possible 
psychological differences between the FM group and the HC group using a web survey tool. The 
scores on these questionnaires can be found in Table 3. (1) Pain severity: The Chronic Pain Grade 
Scale (CPGS)53 assesses pain intensity and interference with normal daily activities using 7 items (e.g., 
How would you rate your pain at this moment?). Answers on 6 of the 7 items range from 0 “no pain” 
to 10 “pain as bad as it could be”. The one remaining item requires filling in the number of days that 
pain has kept respondents from their typical daily activities in the last 6 months (range 0-180). Based 
on the pain intensity score, the disability points (based on the disability score and the days of 
disability) respondents are classified in four grades of chronic pain: Grade I, low disability–low 
intensity; Grade II, low disability–high intensity; Grade III, high disability–moderately limiting; and 
Grade IV, high disability–severely limiting. (2) Pain cognitions: the Pain Cognition List (PCL)49 
consists of 39 items divided into five subscales (Catastrophizing, Limitation, Optimism, Internal 
control  and Trust). Each item presents a specific pain cognition statement (e.g., “My thoughts are 
always concentrated on the pain”) and the respondent is asked to indicate (dis)agreement on a 5-point 
Likert scale. Items are scored from 1 “totally disagree” to 5 “totally agree”, and a sum score is 
obtained per subscale (Catastrophizing: range 16-80; Limitation: range 7-35; Optimism: range 7-35; 
Internal control: range 5-25; Trust: range 4-20). (3) Fear of movement: the Tampa Scale of 
Kinesiophobia (TSK)43 comprises 17 items intended to assess fear of movement and fear of (re)injury. 
Respondents are asked to indicate to what extent each of the statements (e.g., “My body tells me that 
there is something seriously wrong with it”) reflects a true description of the assumed association 
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between movement and (re)injury on a four-point Likert scale, ranging from 1 “strongly disagree” to 4 
“strongly agree” (total score range 17-68). (4) Pain disability: the Fibromyalgia Impact Questionnaire 
(FIQ)5 assesses the impact of fibromyalgia on the respondent’s daily activities. The FIQ is composed 
of 10 items. The first item contains 11 questions (e.g., “Can you independently do the dishes”) related 
to physical functioning – each question is rated on a 4-point Likert type scale. Items 2 and 3 ask the 
respondent to mark the number of days they felt well and the number of days they were unable to 
work (including housework) because of pain symptoms. Items 4 through 10 are horizontal linear 
scales marked in 10 increments on which the respondent rates work difficulty, pain, fatigue, morning 
tiredness, stiffness, anxiety and depression. After normalization, the total score ranges from 0-100, 
with 0 indicating no impairment at all and 100 maximum impairment. (5) Affect: the trait version of 
the Positive and Negative Affect Schedule (PANAS)12, 54 consists of 20 items divided into 2 subscales. 
Participants are asked to indicate to what extent, in their normal daily life, they experience the feelings 
defined by the 20 descriptors using a 5-point response scale ranging from “very little” to “a lot”. Ten 
items describe positive feelings and assess positive affectivity (PA; range 10-50) and 10 items describe 
negative feelings and assess negative affectivity (NA; range 10-50). (6) Depression and anxiety: the 
Hospital Anxiety Depression Scale (HADS)46, 60 consists of 14 items divided into 2 subscales (anxiety 
and depression).  Respondents are asked to indicate for each item (e.g., “I still enjoy the things I used 
to enjoy”) which answer reflects best how they felt during last week. Answers are scored from 0 to 3. 
The scores for the depression subscale and the anxiety subscale range from 0 to 21. (7) Fear of pain: 
The Fear of Pain Questionnaire (FPQ)29, 44 measures fear and anxiety associated with pain. The FPQ is 
composed of 30 items divided into 3 subscales (severe pain, minor pain, and medical pain). 
Respondents are requested to indicate how fearful they would be if they were experiencing the pain 
described in the items (e.g., “Breaking your arm”). Answers are scored from 0 “not fearful” to 5 
“extreme fearful”. (8) Rumination: To explore the way participants typically think about negative 
experiences and problems, we administered the Perseverative Thinking Questionnaire (PTQ)10. This 
questionnaire comprises 15 items. The item pool included three items for each of the characteristics of 
repetitive negative thinking: repetitive, intrusive, difficulty to disengage from, unproductive and 
Running head: EXTINCTION OF GENERALIZATION IN FIBROMYALGIA  
  
                                                                                                                      
 
14 
	
capturing mental capacity. Participants had to rate the extent to which the 15 statements applied to 
them, on a scale ranging from 0 “never” to 4 “almost always”. 
2.7. Response definition and data analysis overview 
2.7.1. Response definition of the startle modulation 
Using PSPHA8, a modular script-based program, we calculated the peak amplitudes defined as 
the maximum of the response curve within 21−175 ms after the startle probe onset. All startle 
waveforms were visually inspected off-line, and technical abnormalities and artifacts were eliminated 
using the PSPHA software. Each peak amplitude was scored by subtracting its baseline score 
(averaged EMG level between 1 and 20 ms after the probe onset). A startle response was rejected if 
the baseline period was contaminated with noise or if a voluntary blink occurred during a 1−20 ms 
time window after probe onset, also when no visual peak could be detected (i.e. non-response), the 
response was rejected. Participants who failed to reach elevated peak amplitudes compared with 
baseline on more than 50% of the trials were considered non-responders and were excluded from 
further analyses. A total of 5 participants (1 HC and 4 FM) were excluded because of the absence of 
reliable startle eyeblink responses. Hence, the statistical analysis of the psychophysiological measure 
was run on a total sample of 55 participants. To make data comparable between individuals, despite 
the inter-individual differences in physiological reactivity, raw scores were transformed to z-scores. 
Furthermore, T-scores (a linear transformation of the z-scores) were used in the figures, to avoid 
negative values on the Y-axis and for an optimized visualization of the startle data. Averages were 
calculated for responding during CS/GS movements and ITI separately for both groups.  
2.7.2 Data analysis overview 
Some preparatory analyses were necessary in order to test our main research questions: First, as 
a manipulation check, we carried out a series of repeated measures ANOVAs to confirm that before 
conditioning both CSs did not differ with respect to affective valence, arousal and control experienced 
when performing the movements, but that after acquisition and generalization the CS+ became more 
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negative, elicited more arousal, and less feelings of being in control than the CS-. Because we had 
clear a priori hypotheses, we further analyzed the data using planned comparisons. The effect size 
indication η!!  is reported for all omnibus ANOVA effects1, 41, and Greenhouse-Geisser corrections 
were applied when appropriate (uncorrected degrees of freedom and corrected p-values are reported 
together with ε). Second, because successful differential fear acquisition is a prerequisite to test fear 
generalization, we checked whether participants reported more fear in response to the CS+ movement 
than to the CS- movement at the end of the (transfer-of-)acquisition training as compared to the 
beginning. Therefore, we defined a random intercept two-level linear regression model to analyze the 
test effects of stimulus type (CS+/CS-) on the change in average pain-related fear ratings during four 
repeated measurements (i.e., during the three blocks of acquisition (A1/A2/A3) and one block of the 
transfer-of-acquisition phase (T1)), nested within persons for both groups (FM and HC) (see online 
supplementary material for the detailed statistical model description). The effects included in this 
model were estimated simultaneously using the SAS procedure MIXED20, 50. The model explains 63% 
of the observed variance in participants’ pain-related fear ratings (see Table S1). We chose to include 
a subject-specific random intercept in the model, given that 48% of the variance was due to 
differences among participants: /(  + ).  Third, we tested the acquisition effects in the startle 
eyeblink measures using a repeated measures ANOVA, that is, whether participants had elevated 
startle responses to the CS+ movement compared to the CS- movement during (transfer-of-) 
acquisition.   
After these preparatory analyses, we proceeded to test our main hypotheses: Following 
Meulders et al.31, we expected that 1) HC would show an immediate transfer of differential pain-
related fear and expectancy learning, whereas FM patients would show an initial loss of differential 
learning due to increased CS- responding, 2) FM patients would show flatter generalization gradients 
than HC and that this is caused by higher responses to the GSs that are more similar to the original CS-
. Testing extinction of fear generalization we expect that 3) FM would show resistance to extinction to 
unreinforced GSs, whereas generalized fear will subside quickly in HC. In order to test the first 
2
θσ
2
θσ
2
εσ
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hypothesis, we defined two two-level linear regression models (one for each dependent variable) with 
two random intercepts (1 for each stimulus type) including group (FM and HC), linear trend variable 
Tj (which equals 0, 1, 2, 3 for trials j = T1, T2, T3, T4), as well as the interaction between the linear 
trend and group. The dependent variables were ratings of pain-US expectancy and fear of movement-
related pain (see online supplementary material for the detailed statistical model description). The 
effects included in this model were estimated simultaneously using the SAS procedure MIXED20, 50. 
Both models are able to predict participants’ pain-US expectancy and fear of movement-related pain 
ratings (see Table S2) very well as they explain 84% and 83%, respectively, of the observed variance 
in ratings. Including random intercepts was necessary as models without random intercepts explain 
respectively only 25% and 18% of the variance in observed ratings. In other words, a substantial part 
of the observed variance in ratings is due to participant differences. 
 In order to test the second and third hypothesis, we defined two two-level linear regression 
models (one for pain-US expectancy and one for fear of movement-related pain) with a subject-
specific random intercept including group (FM and HC), trial (first and last trial of the generalization 
phase), a centered linear trend variable Tk (which equals -3, -2, -1, 0, 1, 2, 3 for trials k = CS+, GS1, 
GS2, GS3, GS4, GS5, GS6, CS-) modeling the linear component of the generalization gradient 
together with a quadratic trend variable (Tk)2 modeling the quadratic component of the generalization 
gradient, as well as the interaction terms between group and the linear (quadratic) trend variable (see 
online supplementary material for the detailed statistical model description). The inclusion of the 
quadratic trend is supported by the data as the models including a quadratic trend have a better balance 
between complexity and goodness-of-fit (i.e., they have lower values of the Bayesian information 
criterion (BIC))45. BIC values for the model including only the linear trend were higher than for the 
model including both the linear and the quadratic trend, for both dependent variables, respectively 
pain-US expectancy: 3914 vs. 3874, and fear of movement-related pain: 3414 vs. 3396. The effects 
included in this model were estimated simultaneously using the SAS procedure MIXED20, 50. Both 
models are able to predict participants’ pain-US expectancy and fear of movement-related pain ratings 
(see Table S3) quite well as they explain 62% and 65%, respectively, of the observed variance in 
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ratings. Including random intercepts was necessary as models without random intercepts explain 
respectively only 22% and 15% of the observed variance in ratings. Hence, a substantial part of the 
observed variance in ratings is due to participant differences.  For all multilevel models, follow-up 
contrasts were calculated to further test our a priori hypotheses. Note that we did not observe a 
generalization gradient in the startle eyeblink measures for neither of the groups; in order not to 
overload the results section these analyses are omitted. Finally, in order to test our fourth hypothesis, 
pain-US intensity and unpleasantness ratings were analyzed using repeated measures ANOVAs to test 
whether pain would be more intense and more unpleasant for FM than for HC. 
We decided to use a mixed analysis strategy combining both the multilevel modeling approach 
and the standard mixed RM ANOVA because unlike standard mixed RM ANOVA the multilevel 
approach (a) can model a quadratic trend, (b) it supports the estimation of a large variety of planned 
contrasts (i.e. all contrasts that can be expressed as a linear function of the underlying regression 
parameters), and (c) it supports the inclusion of random coefficients (e.g. random intercepts). 
Therefore we used the multilevel approach for the analyses where a more flexible approach involving 
these aspects was needed and more complexity also led to a better model fit. Consequently, multilevel 
modeling was used to conduct the manipulation check on fear acquisition in the self-reports and for 
testing hypothesis 1, 2 and 3. In contrast, for the manipulation checks on affective valence, arousal, 
control experienced, and the fear acquisiton in the startle measures, as well as to test hypothesis 4, a 
more standard mixed RM ANOVA turned out be satisfactory. 
3. Results 
3.1 Pain-US characteristics and questionnaires 
In contrast with Meulders et al.31, FM patients did not select a higher pain-US intensity during 
the calibration phase than the HC group, t(58) = 1.54, p = .13. There were also no differences in how 
the selected stimulus was subjectively rated by the FM group and the HC group during the calibration, 
t(58) = 1.40, p = .17, (see Table 1). For the analyses of the questionnaires, one FM patient was 
excluded, because she failed to complete any of the questionnaires. Independent t-tests were 
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conducted using the Holm-Bonferroni method to correct for multiple comparisons. The Holm-
Bonferroni 18correction is based on ranking the p-values of one family of hypotheses from smallest to 
largest. m is the number p-values. If the first p-value is greater than or equal to α/m, the procedure is 
stopped and no p-values are significant. If the first p-value is significant the second p-value is 
compared to α/(m-1), etc. Corrected p-values are reported. As expected, the groups had significantly 
different scores on most of the psychological trait questionnaires (see Table 3). In comparison with the 
HC group, FM patients reported higher pain intensity, t(57)=14.65, p<.0001, greater pain disability, 
t(57)=14.66, p<.0001, and more days of being disabled during the last 6 months, t(57)=3.61, p<.01, 
(P-GRAD-S). The FM group had significantly higher scores on the Catastrophizing, t(57)=4.10, 
p<.01, and the Limitation, t(57)=8.05, p<.0001, subscales, but no significant differences on the 
Optimism, t(57)=-1.79,  p=.48, and Trust, t(57)=-1.23, p=1.00, and Internal Control, t(57)=-2.02, 
p=.33)  subscales of the PCL in comparison with HC. FM reported more fear of movement and 
(re)injury, t(57)=3.51, p<.01, (TSK), reported more impairment in their daily life activities due to pain, 
t(57)=13.56, p<.0001, (FIQ), lower positive affect, t(57)=-5.90, p<.0001, and higher negative affect, 
t(57)=5.30, p<.0001, (PANAS). The FM group significantly differed on the Anxiety, t(57)=-3.13, 
p<.05), but not on the Depression subscale of the HADS, t(57)=-1.15, p=.76, nor did they differ with 
respect to general fear associated with pain as compared to the HC group, t(57)=-0.24, p=.81, (FPQ). 
Furthermore, no differences were found with respect to the FPQ subscales Medical pain, t(57)=-0.86, 
p=.79, and Severe pain, t(57)=-1.15, p=1.00, but FM patients tended to have higher scores for the 
Minor Pain subscale, t(57)=2.82, p=.05. FM patients also reported more repetitive negative thinking, 
t(57)=4.09, p<.0001, than the HC group (PTQ).  
3.2 Manipulation checks 
For all three SAM ratings, we performed a 2 (Group: FM/HC) x 2 (Stimulus Type: CS+/CS-) x 
3 (Phase: Practice/Acq/Gen) mixed RM ANOVA.  
3.2.1 Affective valence of the CS movements  
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This analysis revealed significant main effects for Group, F(1, 58) = 4.80, p<.05, η!!=.03, 
Stimulus Type, F(1, 58) = 37.19, p<.001, η!!=.13, and Phase, F(2,116) = 5.99, p<.01, ε=.94, η!!=.03. 
Further there was a significant Stimulus Type x Phase interaction, F(2, 116) = 26.96, p<.0001, ε=.92, η!!=.09, suggesting that the differences between the CS+ and the CS- changed over the experimental 
phases, this interaction was not modulated by Group, F<1. Planned comparisons further revealed that 
ratings for the CS+ and the CS- did not significantly differ at the end of the practice phase, F<1, but 
after acquisition, participants felt happier when performing the CS- movement than when performing 
the CS+ movement, F(1, 58) = 46.57, p<.001. This difference was still significant after generalization, 
F(1, 58) = 44.61, p<.001. Interestingly, there was no difference between the HC and the FM after 
acquisition and generalization with regards to the affective valence of the painful CS+ movement, F(1, 
58) = 1.08, p=.30, but FM patients were more unhappy when performing the safe CS- movement, F(1, 
58) = 7.45, p<.01. 
3.2.2 Arousal elicited by the CS movements 
This analysis showed a significant main effect for Stimulus Type, F(1, 58) = 24.12, p<.001, η!!=.05. Further there was a significant Stimulus Type x Phase interaction, F(2, 116) = 6.52, p<.01, 
ε=.78, η!!=.02, suggesting that the differences in arousal elicited by the CS+ and the CS- changed over 
the experimental phases, this interaction was not modulated by Group, F<1. Also the Phase x Group 
interaction was significant, F(2, 116) = 5.69, p<.01, ε=.84, η!!=.03, indicating that there was a 
difference between the groups regarding the arousal experienced during the different phases. Planned 
comparisons further confirmed that there were no differences in arousal elicited by the CS+ and the 
CS- at the end of the practice phase in both groups, Fs<1. Interestingly, FM patients reported being 
more aroused when performing both joystick movements before the conditioning procedure than the 
HC, F(1, 58) = 5.34, p<.05. After acquisition however, participants in both groups reported more 
arousal when performing the CS+ movement than when performing the CS- movement, FM: F(1, 58) 
= 5.00, p<.05; HC: F(1, 58) = 11.25, p<.01. This difference was still significant after generalization in 
both groups, FM: F(1, 58) = 11.61 , p<.01; HC: F(1, 58) = 8.99, p<.01. 
Running head: EXTINCTION OF GENERALIZATION IN FIBROMYALGIA  
  
                                                                                                                      
 
20 
	
3.2.3 Feelings of being in control when performing CS movements 
This analysis yielded significant main effects for Stimulus Type, F(1, 58) = 23.48, p<.001, η!!=.05, and Phase, F(2, 116) = 10.21, p<.001, ε=.80, η!!=.05. Further there was a significant Stimulus 
Type x Phase interaction, F(2, 116) = 10.19, p<.001, ε=.86, η!!=.05, suggesting that the differences in 
control experienced during the CS+ and the CS- changed over the experimental phases, this interaction 
was not modulated by Group, F<1. The Phase x Group interaction also reached significance, F(2, 116) 
= 5.81, p<.01, ε=.80, η!!=.03, indicating that there was a difference between the groups regarding the 
control experienced during the different phases. Planned comparisons further confirmed that there 
were no differences in control experienced during the CS+ and the CS- at the end of the practice phase 
in both groups, HC: F<1; FM: F(1, 58) = 3.99, p=.051. After acquisition however, participants in both 
groups reported feeling more in control when performing the CS- movement than when performing 
the CS+ movement, FM: F(1, 58) = 16.67, p<.001; HC: F(1, 58) = 11.07, p<.01. This difference was 
still significant after generalization in both groups, FM: F(1, 58) = 14.86 , p<.001; HC: F(1, 58) = 
12.74, p<.001. 
3.2.4 Acquisition of self-reported fear of movement-related pain  
Self-reported fear of movement-related pain acquisition was tested using a multilevel 
regression model (see online supplementary material for the detailed statistical model description). 
Table S1 (see online supplementary material) presents the results of the multilevel regression model 
for fear of movement-related pain ratings during (transfer-of-)acquisition, follow-up planned contrasts 
are visualized in Figure 2. When reporting planned contrasts ( )ˆ klS  indicates the estimated slope for 
stimulus k (CS+, CS-) in group l (HC, FM) and ( )ˆ ( )kjY l represents the predicted rating for stimulus k 
(CS+, CS-) at block j (A1, A2, A3, T1) in group l (HC, FM). 
 There was a significant effect of time on the acquisition of fear of movement-related pain, 
indicating successful fear acquisition to the CS+, but not to the CS- (see Figure 2). This was indicated 
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by a significant difference in slopes for the CS+ and the CS- in both groups ( ( ) ( )ˆ ˆ 0.93FM FMS S
+ −− = , p < 
.0001; ( ) ( )ˆ ˆHC HCS S
+ −−  = 0.55, p < .05). Differential fear of movement-related pain was already acquired at 
the first rating moment A1 (that is, after four movements of each type) in the HC, that is, they reported 
higher fear in response to the CS+ than the CS- (γ1 = 1.26, p < .01), whereas this was not the case for 
the FM (γ2 = 0.76, p = .06). At the last rating moment T1 (after the transfer-of-acquisition phase) the 
fear elicited by the CS+ was significantly higher compared with the CS- movement in both groups (γ3 
= 2.90, p < .0001; γ4 = 3.54, p < .0001). These results indicate that participants in both groups learned 
to be afraid of the CS+ movement, but not the CS- movement; however, this differential learning was 
acquired slower by the FM than the HC. 
3.2.5 Acquisition of fear-potentiated eyeblink startle  
A 2 (Group: FM/HC) x 3 (Stimulus Type: CS+/CS-/ITI) x 4 (Block: A1-A3, T1) mixed RM 
ANOVA was carried out to test acquisition of differential fear learning in the eyeblink startle 
measures (see Figure 3). The results showed a significant main effect for Block, F(3, 159) = 3.03, 
p<.05, ε=.92, η!!=.02, indicating habituation, that is, startle responses declined gradually over time, but 
increased again during the transfer-of-acquisition phase probably because the change in procedure 
elicited an orientation response. Importantly, there was a significant main effect of Stimulus Type, 
F(2, 106) = 4.11, p<.05, ε=.94, η!!=.02. The Block x Stimulus Type interaction however just failed to 
reach significance, F(6, 318) = 2.16, p=.05, ε=.89, η!!=.02. The main effect of Group and all the 
interactions with this variable were not significant. Planned comparisons further confirmed that in both 
groups, the mean startle eyeblink amplitudes were elevated during the CS+ movement as compared to 
the CS- movement, F(1, 53) = 10.95, p<.01. These data confirm that participants in both groups 
successfully acquired similar levels of differential eyeblink startle responding. 
3.3  Testing our primary hypotheses  
Hypothesis 1: Differences in transfer-of-acquisition between healthy controls and fibromyalgia 
patients for pain-US expectancy and fear of movement-related pain ratings 
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Table S2 (see online supplementary material) presents the results of the multilevel regression 
model for the pain-US expectancy and fear of movement-related pain ratings during the four trials of 
the transfer-of-acquisition phase, follow-up planned contrasts are depicted in Figure 4.  When 
reporting planned contrasts ( )ˆ ( )kjY l  is used to indicate the predicted rating for stimulus k (CS+, CS-) at 
trial j (T1, T2, T3, T4) in group l (HC, FM). At T1 (the first trial of the transfer-of-acquisition phase, 
see Figure 4a) HC still expected the pain-US to occur more after the CS+ than after the CS- (γ5 = 3.37, 
p<.0001). In contrast with our expectations, FM also showed differential pain-US expectancies for the 
CS+ and the CS- at T1 (γ6 = 1.61, p<.05), but the transferred CS+/CS- difference was not significantly 
smaller in the FM than the HC (γ6 –γ5 = -1.76, p=.07). At T4, both groups showed stable differential 
pain-US expectancies for the CS+ and the CS- (HC: γ7 = 4.47, p<.0001; FM: γ8 = 2.88, p<.0001). 
Interestingly, the pain-US expectancies in response to the CS+ did not differ between both groups (γ9, 
γ10, γ11, γ12)  at any of the transfer-of-acquisition trials, but FM expected the pain-US to occur more 
when performing the CS- than the HC, T1: γ13 = 2.06, p<.01; T2: γ14 = 1.88, p<.01; T3: γ15 = 1.70, 
p<.01; T4: γ16 = 1.53, p<.05, which is indicative of fragile safety learning (see Figure 4b).  
Similarly, for the fear of movement-related pain ratings, at T1 (the first trial of the transfer-of-
acquisition phase, see Figure 4c) HC reported to be more afraid to perform the CS+ movement than 
the CS- movement (γ17 = 1.51, p<.01). In line with our expectations, FM did not transfer the acquired 
CS+/CS- differential fear learning and thus were equally afraid to perform the CS+ and the CS- 
movement at T1 (γ18 = 0.88, p=.09). As expected, this lack of differentiation was due to elevated fear 
responses for the CS- in the FM as compared with the HC (T1: γ19 = 1.71, p<.001; T2: γ20 = 1.53, 
p<.001; T3: γ21 = 1.35, p<.01; T4: γ22 =  1.18, p<.05, whereas no such differences were observed for 
the CS+ (γ23, γ24, γ25, γ26). At T4, both groups reliably reported more pain-related fear to the CS+ than to 
the CS- (HC: γ27 = 2.49, p<.0001; FM: γ28 = 2.76, p<.0001) (see Figure 4d). 
Hypothesis 2: Differences in generalization between healthy controls and fibromyalgia patients 
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Table S3 (see online supplementary material) presents the results of the multilevel regression 
model for the pain-US expectancy and fear of movement-related pain ratings during the first and the 
last trial of the generalization phase, follow-up planned contrasts are visualized in Figure 5. Note that 
when reporting contrasts ( )ˆ ( )kjY l represents the predicted rating for stimulus k (CS+, GS1, GS2, GS3, 
GS4, GS5, CS-) at trial j (t1,t4) in group l (HC, FM). The generalization effect is expected to be the 
largest at trial 1, and to extinguish in the following trials, therefore the difference in generalization 
between the HC and FM patients is assessed at trial 1 and differences in extinction of generalization 
are assessed at trial 4 (and differences from trial 1 to trial 4). As predicted, there was a significant 
difference in the slope of the linear trend at the first trial of the generalization phase between both 
groups, (1)
LINxG
β = 0.25, p<.05, indicating that FM showed flatter pain-US expectancy generalization 
gradients as compared with the HC. Planned comparisons (see Figure 5a) further confirmed that this 
difference in steepness of the slopes is explained by differences at the CS- side of the generalization 
gradient (i.e. responses to novel movements that are more similar to the safe movements), but that no 
differences occurred at the CS+ side of the generalization gradient (i.e. responses to novel movements 
that are more similar to the painful movements). More particularly, FM reported significantly higher 
pain-US expectancies for the CS- (γ29 = 2.23, p<.01), and GS5 (the generalization movement that was 
most similar to the CS-), γ30 = 1.46, p<.05, than the HC; the pain-US expectancy ratings for the other 
GSs and the original CS+ however did not differ between both groups (γ31, γ32, γ33, γ34, γ35).  
A similar data pattern was observed in the fear of movement-related pain ratings, however the 
statistical analyses did not fully corroborate our findings in the pain-US expectancy ratings. The linear 
trend variable did not interact with group, (1)
LINxG
β = -.02, p=.78, suggesting that the steepness of the 
slopes for the HC and FM did not significantly differ for the fear of movement-related pain ratings. 
The quadratic trend tended to be different in both groups, but this difference was not statistically 
significant, (1)
QUADxG
β = .08, p=.08. Planned contrasts (see Figure 5b) further showed that FM were more 
afraid of the original CS- (γ36  = 1.27, p<.05), than HC, but they also reported more fear of movement-
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related pain in response to the original CS+ (γ37 = 1.40, p<.05); these elevated fear responses seemed 
to spread on both sides of the generalization gradient, but failed to reach significance (GS1: γ38 = 1.00, 
p=.07, and GS5: γ39 = 0.91, p=.09). The fear of movement-related pain ratings for the other GSs did 
not differ between both groups (γ40, γ41, γ42).  
Taken together, these results provide partial evidence for our hypothesis: pain-US expectancy 
generalization gradients are flatter in FM than HC due to elevated pain-US expectancies for the 
technically safe movements whereas the shape of the fear generalization gradient is not significantly 
different between FM and HC, but fear responses seem to be elevated on both sides of the continuum 
in FM. 
Hypothesis 3: Differences in extinction of generalization between healthy controls and fibromyalgia 
patients 
Predicted ratings of pain-US expectancy and fear of movement-related fear are depicted in 
Figure 5. At trial 4, there was a significantly different slope in the pain-US expectancy ratings for the 
FM vs. HC, (4)
LINxG
β = 0.22, p<.05. Planned contrasts (see Figure 5c) further showed that pain-US 
expectancies in response to all GSs decreased significantly from trial 1 to trial 4 for the HC (γ43 = 1.47, 
γ44 = 2.41, γ45 = 2.77, γ46 = 0.35, γ47 = 1.71; all ps<.0001), but not for the CS+ (γ48 = -0.06, p=.91),  that 
remained reinforced during the generalization phase, and not for the CS- (γ49 = 0.30, p=.56) (i.e. floor 
effect). The pain-US expectancy ratings for the FM also declined significantly from trial 1 to trial 4 for 
GS2 (γ50 = 1.19), GS3 (γ51 = 1.42), GS4 (γ52 = 1.36), and GS5 (γ53 = 1.03; all ps<.01) but not for the 
CS+ (γ54 = -0.10, p=.84), the CS- (γ55 = 0.42, p=.42), and the GS1 (γ56 = 0.68, p=.05). Interestingly, the 
decline in pain-US expectancies for GS2 (γ56 – γ43 = -1.22), GS3 (γ50 – γ44 = -1.35), and GS4 (γ51 – γ45= 
-1.17; all ps<.05), was significantly smaller in the FM group than the HC, suggesting that there was 
resistance to extinction of pain-US expectancies to the novel, unreinforced generalization movements. 
At trial 4, the pain-US expectancies for all GSs (GS1: γ57 = 1.26, p<.05; GS2: γ58 = 1.64, p<.01; GS3: 
γ59 = 1.91, p<.001; GS4: γ60 = 2.08, p<.001; GS5: γ61 = 2.15, p<.0001), and the CS- (γ62= 2.11, p<.01), 
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were indeed still significantly higher for the FM than the HC, which further supports the resistance to 
extinction of generalization hypothesis (see Figure 5a).  
A similar analysis was run on the fear of movement-related pain ratings, however this analysis 
could only partly confirm our findings in the pain-US expectancy ratings. At trial 4, there was no 
significantly different slope in fear of movement-related pain ratings for the FM vs. HC, (4)
LINxG
β = -0.05, 
p=.51. Planned contrasts (see Figure 5d) further showed that fear in response to all GSs decreased 
significantly from trial 1 to trial 4 for the HC, (GS1: γ63 = 0.66, p<.05; GS2: γ64 = 0.98, p<.001; GS3: 
γ65 = 1.09, p<.0001; GS4: γ66 = 1.00, p<.001; GS5: γ67 = 0.70, p<.01), but not for the CS+ (γ68 = 0.15, 
p=.69),  that remained reinforced during the generalization phase, and not for the CS- (γ69 = 0.22, 
p=.57) (i.e. floor effect). The fear of movement-related pain ratings for the FM also declined 
significantly from trial 1 to trial 4 for GS2 (γ70 = 0.73, p<.01), GS3 (γ71 = 0.86, p<.01), GS4 (γ72 = 0.81, 
p<.01),and GS5 (γ73 = 0.59,  p<.05), but not for the CS+ (γ74 = -0.06, p=.87), the CS- (γ75 = 0.18, 
p=.63), and the GS1 (γ76 = 0.42, p=.10). The decline in fear of movement-related pain was not 
significantly smaller in the FM group than the HC (see Table 9). At trial 4, however the fear of most 
generalization movements was still significantly higher for the FM than the HC, (GS1: γ77 = 1.24, 
p<.01; GS2: γ78 = 0.99, p<.05; GS3: γ79 = 0.87, p=.06; GS4: γ80 = 0.89, p=.05; GS5: γ81 = 1.03, p<.05), 
which at least provides partial support for the resistance to extinction of generalization hypothesis (see 
Figure 5c). 
Hypothesis 4: Differences in pain-US intensity and unpleasantness between healthy controls and 
fibromyalgia patients 
We examined the differences in self-reported intensity and unpleasantness of the pain-US by 
performing 2 mixed RM ANOVAs including Group (FM/HC) and Block (A1-A3, T1, GEN). These 
analyses yielded significant main effect of Group (unpleasantness: F(1, 58) = 4.91, p<.05, η!!=.10 
intensity: F(1, 58) = 8.26, p<.05, η!!=.06). The main effect and the interaction with Block failed to 
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reach significance in both analyses. These results confirm that FM rated the selected pain-US as more 
painful and more unpleasant throughout the experiment than the HC. 
4. Discussion 
To our knowledge, this is the first study that investigated the differences in generalization 
gradients of pain-related fear and expectancy between fibromyalgia patients (FM) and age- and 
gender-matched healthy pain-free controls (HC), and subsequently compared the rate of extinction of 
generalization between both groups. We hypothesized that FM would show (1) poorer transfer of 
safety learning to a novel context, (2) flatter generalization gradients compared to HC due to higher 
responses to the GSs that are more similar to the original CS-, (3) impaired extinction of unreinforced 
GSs, whereas generalized pain-related fear and expectancy will subside quickly in HC, and (4) higher 
levels of pain unpleasantness and intensity than HC. 
The results can be summarized as follows: First, we successfully established acquisition of 
fear of movement-related pain in both groups. This effect was evident by elevated startle amplitudes, 
higher pain-related fear and expectancy ratings for the CS+ than for the CS-. Participants also felt 
unhappier, less in control and more aroused while performing the CS+ movement compared to the CS- 
movement. Interestingly, whereas HC acquired these CS-US contingencies after only one acquisition 
block, it took longer for FM to pick up on these relationships. Second, as predicted, FM showed poorer 
transfer of safety learning to a novel context than HC. During the transfer-of-acquisition phase, we 
switched from a voluntary to a signaled movement set-up, implying that participants needed to transfer 
the acquired CS-US contingencies to a novel context. HC did transfer these contingencies impeccably 
and showed differential fear responses to the CS+/- from the first trial on, but FM did not. These 
results seem to suggest that once adaptive differential fear learning is acquired, it is fragile and 
sensitive to context switches in FM. Furthermore, fear responses during the CS+ did not differ 
between groups, but CS- responses were elevated in FM compared with HC, indicating disruptive 
safety learning. This pattern was not completely mirrored in the pain-US expectancy measures; no loss 
of transfer of differential learning was observed. Nevertheless, again pain-US expectancies in response 
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to the CS- were elevated for FM as compared with HC, whereas no such differences were observed for 
the CS+. These findings also provide evidence for the fragility of safety learning in FM. The 
vulnerability of safety learning can be understood in terms of the associative learning theory. That is, 
safety learning can be seen as inhibitory learning to the CS-. In contrast to excitatory learning to the 
CS+, which generalizes easily to new contexts, safety learning to the CS- is a form of inhibitory 
learning like extinction learning, which is a more fragile learning process that is under contextual 
control. Nowadays, extinction is commonly viewed as acquiring a new CS-noUS association that 
inhibits the behavioral expression of the first learned association rather than the forgetting/overwriting 
of the original CS-US association3. As a consequence, which of both co-existing associations controls 
behavior is context-dependent. The effect observed in our study is very similar to renewal (i.e. a return 
of fear after successful extinction due to a context switch) because the acquired safety learning 
disappears when a context change occurs (i.e. signaled versus voluntary movement set-up). These 
findings corroborate previous findings of Meulders et al.31, and suggest that FM, who seem to be 
characterized by fragile safety learning, might have difficulties transferring CS-noUS contingencies to 
other contexts. Third, with respect to fear generalization, we replicated and extended our previous 
findings using a design in which the GSs either had a feature in common with the CS+ or CS- but no 
generalization gradients could be calculated31. More specifically, we showed that pain expectancy 
generalization gradients are flatter in FM than in HC due to elevated pain expectancies for the novel, 
technically safe movements, whereas the shape of the fear generalization gradient did not differ 
between both groups. These findings are also in line with our study on pain expectancy judgments in 
chronic hand pain patients30. Fourth, with respect to extinction of generalization, we found at least 
partial evidence for our hypothesis: we showed that although the pain expectancy for all generalization 
movements declined for HC and for all but the GS1 in FM, this decline was still significantly smaller 
in FM than in HC. Moreover after four unreinforced trials, pain expectancies for all generalization 
movements remained elevated for FM compared to HC. A similar pattern was observed in the pain-
related fear ratings, fear in response to all generalization movements declined for the HC and for all 
but the GS1 in the FM, this decline was however was not significantly different in FM than in HC. 
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Nevertheless, after four unreinforced trials, pain-related fear of most of the generalization movements 
remained elevated for the FM compared to the HC. These results suggest a deficiency in the extinction 
of fear generalization in FM patients, which may contribute to the maintenance of chronic disability in 
patients. Closely related, Flor and colleagues previously demonstrated that, relative to HC, chronic 
back pain patients showed similar rates of acquisition, but slower extinction of verbal as well as 
cortical pain responses13. The current findings are also in line with previous research on fear extinction 
in anxiety disorder patients. For example, Wessa and Flor56 reported that PTSD patients have a deficit 
in extinction of traumatic response. Michael et al.39 conducted a study with panic disorder (PD) 
patients and found that PD patients too showed impaired extinction learning. The current findings 
corroborate previous research in anxiety disorders that found differences in fear extinction between 
HC17, 40 and, essentially extend these findings by showing impaired extinction of generalization. 
Previous research also showed that safety learning is particularly vulnerable in individuals with high 
trait anxiety and relatively low levels of positive affect32. In the present study, FM scored relatively 
high on trait anxiety, and low on positive affect, and showed fragile safety learning, which further 
corroborates previous findings. Fifth, FM tended to select a lower intensity, however, the physical 
intensity did not significantly differ from HC. FM rated the selected pain-US as more intense and 
more unpleasant than HC, which might be due to increased pain sensitivity, corroborating previous 
observations42.  
There are some limitations that should be addressed as well. First, five participants were 
excluded from the startle analyses. Due to reduced statistical power, general interactions might have 
failed to reach statistical significance. Second, only one male participated in our study, so the results 
cannot necessarily be generalized to a male population. However, women are affected with FM about 
three times more often than men28. Therefore, it can be argued that our sample composition is justified. 
Third, no conclusions can be drawn about the causal relationship between impaired safety learning and 
overgeneralization of pain-related fear in FM, because we did not use a longitudinal design, which is 
needed to draw such conclusions. Future research might use longitudinal designs to investigate the 
causal relationship of fear learning deficits in the origin and maintenance of FM. Fourth, the groups 
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also differed with respect to medication use6, 11, 16 and comorbidity with anxiety and depression21, 26, 27 
thus we cannot exclude the possibility that this might have contributed to the observed differences in 
fear learning/expression. Indeed, impaired safety learning27, fear overgeneralization25, 26 and resistance 
to extinction39, 56 has been reported in anxiety disorder patients as well. Moreover, anxiolytics might 
affect the expression of context conditioning15, opioids have shown to impair fear learning11, and 
antidepressants may enhance cued fear conditioning7, 16. However, given the possible opposite effects 
of the different drugs used in our patient group, it is rather unlikely that the medication use explains all 
the observed variance between FM and HC.  
Fear generalization research explains how stimuli that were never associated with pain 
themselves may trigger fear. From a clinical perspective, an extensive analysis of crucial stimuli and 
their conditioning history should be fed back into exposure treatment –the clinical analogue of 
Pavlovian extinction and golden standard for fear reduction. Exposure treatment often involves GSs 
because the original CSs are unavailable/inaccessible. Previous research has shown that extinction of 
the original CS spreads to GSs51, but not necessarily the other way around. The observation that FM 
show slower extinction of generalized fear may thus be especially problematic for exposure treatment 
responsivity. A plausible way to overcome this deficit, is to use a broad array of GSs (by analogy of 
exposure in different contexts to promote the generalization of extinction)9. 
To conclude, this study showed poorer transfer of safety learning to a novel context in FM 
than HC. Further, results provided partial evidence for our overgeneralization hypothesis: pain 
expectancy generalization gradients were flatter in FM than HC due to elevated pain expectancies for 
the technically safe movements whereas the shape of the fear generalization gradient was not different 
for FM and HC. Fearful responding declined to the generalization movements in both groups, but 
extinction of generalization of pain-related fear and expectancy was impaired in FM as compared to 
HC. We contend that this failure of extinction of generalization might be a contributing factor in the 
exacerbation and maintenance of fibromyalgia syndrome pathology and disability. 
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Figure Captions 
Figure 1. Schematic overview of the experimental task during the generalization phase. 
Figure 2. Predicted difference of fear of movement-related pain ratings in response to CS+ and CS- 
movements during acquisition (A1-3) and transfer-of-acquisition (T) for both groups (HC and FM). 
Figure 3. Mean eyeblink startle amplitudes (±SE’s) during the CS movements and the ITI during 
(transfer-of -)acquisition. Note – that for graphic purposes T-scores were used. 
Figure 4. Predicted difference in (a) pain-US expectancy ratings (CS+ minus CS-) for both groups 
(HC and FM), (b) pain-US expectancy ratings (FM minus HC) for both CSs, (c) fear of movement-
related pain ratings (CS+ minus CS-) for both groups (HC and FM), and (d) fear of movement-related 
pain ratings (FM minus HC) for both CSs during the four trials of the transfer-of-acquisition (T1-4). 
Figure 5. Predicted difference in (a) pain-US expectancy ratings (FM minus HC) at the first trial (T1) 
and last trial (T4) of the generalization phase, (b) fear of movement-related pain ratings (FM minus 
HC) at the first trial (T1) and last trial (T4) of the generalization phase, (c) pain-US expectancy ratings 
(T1 minus T4) for both groups (HC and FM), and (d) fear of movement-related pain ratings (T1 minus 
T4) for both groups (HC and FM).  
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Table 1. Demographic and clinical characteristics for the fibromyalgia (FM) group (n=30) and the healthy control (HC) group (n=30) separately. 
Total N = 60 FM group HC group       
  Mean SD Mean SD t df 
Selected pain intensity level (in mA) 18.73 8.53 22.90 12.18 1.54 58 
Selected self-reported pain intensity (range 1-10) 7.87 0.35 7.98 0.18 1.40 58 
Age (in years) 40.80 11.28 40.63 11.98 -0.06 58 
WPI (range 0-19) 9.43 3.89 
    SS (range 0-12) 8.13 1.66 
    Highest education level            
Primary school 10% 
 
0% 
   Vocational secondary education 23% 
 
0% 
   Technical secondary education 17% 
 
10% 
   General secondary education 7% 
 
13% 
   Professional bachelor’s degree 10% 10% 
Academic bachelor’s degree 20% 
 
47% 
   Master’s degree 3% 
 
17% 
   Other 10% 3% 
Type of medication 
   	 	 	Antidepressants 40% 
 
0% 
	 	 	Anxiolytics 20% 
 
0% 
	 	 	Analgesics (opioids) 33% 
 
0% 
	 	 	Analgesics (non-opioids) 43% 
 
0% 
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Other 47%   7% 		 		 		
Note – WPI = Widespread Pain index: the higher the score, the more pain complaints on different sites of the body during the past week;  SS = Symptom Severity Score: 0 = 
no symptoms, 12  =  very much pain symptoms. Other medication includes: muscle relaxants, hormones, anti-hypertension, antiarrhythmic, gastric ulcer medication, 
dopamine, synthetic thyroid hormone, psoriasis medication, magnesium supplements, and probiotics. 
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Note – CS = conditioned stimulus (movement quadrant 1 and 7); GS = generalization stimulus (movement quadrants 2-6); pain-US = painful electrocutaneous 
stimulus (2 ms duration); CS+ and CS-, respectively, refer to the movement direction that is followed by the pain-US (75% reinforcement) and the movement 
that is never followed by the pain-US. The suffix "only" is used to indicate non-reinforcement of the CS+ movement (i.e. during the practice phase). GS 
movements are never reinforced. Both groups (FM and HC) were subjected to the same experimental procedure. 
	
  
Table 2. Study design summary 
   Practice 
(2 x 8 trials) 
Habituation 
(8 trials) 
Acquisition 
(3 x 8 trials) 
Transfer-of-acquisition 
(1 x 8 trials) 
Generalization 
(4 x 7 trials) 
2 x [4 x CS+ only] 8 probes 3 x [4 x CS+] 4 x CS+ 4 x CS+ 
2 x [4 x CS-] 
 
3 x [4 x CS-] 4 x CS- 4 x CS- 
    
4 x GS1-5 
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Table 3. Questionnaire scores for the fibromyalgia (FM) group and healthy control (HC) group separately. 
  Total sample N=59 FM group (n = 29) HC group  (n = 30)     
  Mean SD Mean  SD t df 
CPGS – pain intensity* 65.29 14.18 15.56 11.82 14.65 57 
CPGS – pain disability* 56.90 17.36 5.22 8.29 14.66 57 
CPGS – number of days disability* 44.90 66.47 1.00 2.85 3.61 57 
PCL – catastrophizing* 44.17 13.36 30.23 12.75 4.10 57 
PCL – limitation* 27.14 5.12 16.20 5.31 8.05 57 
PCL – optimism  23.86 4.31 26.37 6.26 -1.79 57 
PCL – internal control 16.1 4.18 18.20 3.77 -2.02 57 
PCL – trust 13.41 2.82 14.40 3.32 -1.23 57 
TSK – total score* 41.07 7.93 34.33 6.80 3.51 57 
FIQ – total score* 55.35 15.15 13.82 7.09 13.56 57 
PANAS – positive affect* 30.45 7.87 40.43 4.82 -5.90 57 
PANAS – negative affect* 24.14 8.53 14.97 4.06 5.30 57 
HADS – anxiety* 17.72 3.24 19.90 1.97 -3.13 57 
HADS – depression 15.45 2.23 16.00 1.36 -1.15 57 
FPQ – medical pain 18.90 6.76 20.27 5.41 -0.86 57 
FPQ – minor pain 16.72 4.98 13.67 3.19 2.82 57 
FPQ – severe pain 24.14 8.36 26.73 8.91 -1.15 57 
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FPQ – total score 59.76 16.30 60.67 13.16 -0.24 57 
PTQ – total score * 27.76 13.79 14.30 11.42 4.09 57 
Note – *p<.05, after Holm-Bonferroni corrections. One patient failed to fill out the questionnaires. Based on the CPGS scales, 10% (3/29) of the fibromyalgia patients was 
classified as Grade I (low disability - low intensity), 28% (8/29) as Grade II (low disability - high intensity), 14% (4/29) as Grade III (high disability - moderately limiting) 
and 48% (14/29) as Grade IV (high disability - severely limiting). 
CPGS = Chronic Pain Grade Scale: pain intensity (item 1-3), pain disability (item 4-6) and days of disability (item 7); PCL = Pain Cognition List: subscales are calculated for 
catastrophizing, limitation, optimism, internal control and trust; TSK = total score of Tampa Scale of Kinesiophobia; FIQ = total score of Fibromyalgia Impact Questionnaire; 
PANAS = Positive and Negative Affect Schedule: subscales are calculated for positive affect and negative affect; HADS  = Hospital Anxiety Depression Scale: subscales are 
calculated for anxiety and depression; FPQ = total score of Fear of Pain Questionnaire: subscales are calculated for medical pain, minor pain, and severe pain; PTQ = total 
score of Perseverative Thinking Questionnaire.  
	  
Running head: EXTINCTION OF GENERALIZATION IN FIBROMYALGIA  
  
                                                                                                                      
 
48 
	
Table S1. Results of the multilevel regression model predicting retrospective fear of movement-related pain ratings for CS+ versus CS- during 
the acquisition and transfer-of-acquisition phases for subjects in the control (HC) group versus fibromyalgia (FM) group. 
Coefficient Description Estimate SE p-value 
( )µ −  Predicted intercept of the linear trend (i.e. at T=0) for CS- for HC with an average random 
intercept value (i.e. 0iθ = ) 
0.97 0.43 0.026 
( )
Tβ
−  Slope of the linear trend of CS- for HC -0.07 0.15 0.661 
( )
Gβ
−  Increase in the intercept of the linear trend (i.e. at T=0) of CS- for HC vs. FM 1.10 0.61 0.072 
( )
TxGβ
−  Increase in the slope of the linear trend of CS- for HC vs. FM -0.10 0.21 0.641 
( )µ +  Predicted intercept of the linear trend (i.e. at T=0) for CS+ for HC with an average 
random intercept value (i.e. 0iθ = ) 
2.23 0.43 <.0001 
( )
Tβ
+  Slope of the linear trend of CS+ for HC 0.48 0.15 0.002 
( )
Gβ
+  Increase in the intercept of the linear trend (i.e. at T=0) of CS+ for HC vs. FM 0.60 0.61 0.328 
( )
TxGβ
+  Increase in the slope of the linear trend of CS+ for HC vs. FM 0.28 0.21 0.193 
2
θσ  Variance of the subject-specific predicted ratings at block A1 (i.e. T=0) 3.16 0.67 <.0001 
2
εσ  Variance of the error term 3.45 0.24 <.0001 
R2 Proportion of explained variance 62.8%   
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Table S2. Results of the multilevel regression models predicting fear of movement-related pain and pain-US expectancy ratings for CS+ versus 
CS- during the transfer-of-acquisition phase for subjects in the control (HC) group versus the fibromyalgia (FM) group.  
Regression model predicting pain-US expectancy 
Coefficient Description Estimate SE p-value 
( )µ −  Predicted intercept of the linear trend (i.e. at T=0) for CS- for HC with an average random 
intercept value (i.e. ( ) 0CSiθ
− = ) 2.550 0.459 <.0001 
( )
Tβ
−  Slope of the linear trend of CS- for HC -0.283 0.127 0.027 
( )
Gβ
−  Increase in the intercept of the linear trend (i.e. at T=0) of CS- HC vs. FM 2.057 0.650 0.002 
( )
TxGβ
−  Increase in the slope of the linear trend of CS- HC vs. FM -0.177 0.180 0.327 
( )µ +  Predicted intercept of the linear trend (i.e. at T=0) for HC with an average random 
intercept value (i.e. ( ) 0CSiθ
+ = ) 5.917 0.570 <.0001 
( )
Tβ
+  Slope of the linear trend of CS+ for HC 0.083 0.127 0.513 
( )
Gβ
+  Increase in the intercept of the linear trend (i.e. at T=0) of CS+ for HC vs. FM 0.297 0.807 0.713 
( )
TxGβ
+  Increase in the slope of the linear trend of CS+ for HC vs. FM -0.120 0.180 0.505 
2
( )CSσ −  Variance of the subject-specific predicted ratings for CS- at T1 (i.e. T=0) 4.633 0.974 <.0001 
2
( )CSσ +  Variance of the subject-specific predicted ratings for CS+ at T1 (i.e. T=0) 8.058 1.610 <.0001 
2
εσ  Variance of the error term 2.428 0.182 <.0001 
R2 Proportion of explained variance 84.0%   
Regression model predicting fear of movement-related pain ratings 
Coefficient Description Estimate SE p-value 
( )µ −  Predicted intercept of the linear trend (i.e. at T=0) for CS- for HC with an average random 
intercept value (i.e. ( ) 0CSiθ
− = ) 1.270 0.361 0.001 
( )
Tβ
−  Slope of the linear trend of CS- for HC -0.247 0.112 0.029 
( )
Gβ
−  Increase in the intercept of the linear trend (i.e. at T=0) of CS- for HC vs. FM 1.707 0.510 0.001 
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( )
TxGβ
−  Increase in the slope of the linear trend of CS- for HC vs. FM -0.177 0.159 0.266 
( )µ +  Predicted intercept of the linear trend (i.e. at T=0) for CS+ for HC with an average 
random intercept value (i.e. ( ) 0CSiθ
+ = ) 2.780 0.549 <.0001 
( )
Tβ
+  Slope of the linear trend of CS+ for HC 0.080 0.112 0.476 
( )
Gβ
+  Increase in the intercept of the linear trend (i.e. at T=0) of CS+ for HC vs. FM 1.073 0.777 0.168 
( )
TxGβ
+  Increase in the slope of the linear trend of CS+ for HC vs. FM 0.123 0.159 0.437 
2
( )CSσ −  Variance of the subject-specific predicted ratings for CS- at T1 (i.e. T=0) 2.580 0.568 <.0001 
2
( )CSσ +  Variance of the subject-specific predicted ratings for CS+ at T1 (i.e. T=0) 7.733 1.524 <.0001 
2
εσ  Variance of the error term 1.887 0.141 <.0001 
R2 Proportion of explained variance 82.7%   
	
	 	
Running head: EXTINCTION OF GENERALIZATION IN FIBROMYALGIA  
  
                                                                                                                      
 
51 
	
Table S3.  Results of the multilevel regression models predicting pain-US expectancy and fear of movement-related pain ratings for the 
conditioned (CS+ and CS-) and generalization stimuli (GS1-5) at trial 1 and trial 4 of the generalization phase for subjects of the control group 
versus fibromyalgia group. 
Regression model predicting pain-US expectancy 
Coefficient Description Estimate SE p-value 
(1)µ  Predicted rating at trial 1 for GS3 (i.e. T=0) for HC (i.e. 0G = ), and an average random intercept 
value (i.e. 0iθ = ) 
3.651 0.445 <.0001 
(1)
LIN
β  Average change in the predicted rating at trial 1 for GSk compared with GSk-1 for HC (i.e. 0G = ) -0.593 0.073 <.0001 
(1)
QUAD
β  Half of the expected change in the slope of the linear trend for trial 1 for GSk compared with GSk-1 
for HC (i.e. 0G = ) -0.044 0.042 0.303 
(1)
G
β  Average difference in the predicted rating at trial 1 for GS3 (i.e. T=0) for HC vs. FM 0.560 0.629 0.373 
(1)
LINxG
β  Difference in the slope of the linear trend at trial 1 for HC vs. FM 0.246 0.104 0.018 
(1)
QUADxG
β  Half of the difference in the expected change in the slope of the linear trend at trial 1 for GSk 
compared with GSk-1 for HC vs. FM 
0.103 0.060 0.087 
(4)µ  Predicted rating at trial 4 for GS3 (i.e. T=0) for HC (i.e. 0G = ), and an average random intercept 
value (i.e. 0iθ = ) 
0.884 0.396 0.029 
(4)
LIN
β  Average change in the predicted rating at trial 4 for GSk compared with GSk-1 for HC (i.e. 0G = ) -0.654 0.073 <.0001 
(4)
QUAD
β  Half of the expected change in the slope of the linear trend at trial 4 for GSk compared with  GSk-1 
for HC (i.e. 0G = ) 0.250 0.042 <.0001 
(4)
G
β  Average difference in the predicted rating at trial 4 for GS3 (i.e. T=0) for HC vs. FM 1.910 0.560 0.0007 
(4)
LINxG
β  Difference in the slope of the linear trend at trial 4 for HC vs. FM 0.220 0.104 0.034 
(4)
QUADxGβ  Half of the difference in the expected change in the slope of the linear trend at trial 4 for GSk 
compared with GSk-1 for HC vs. FM 
-0.051 0.060 0.393 
2
(1)σ  Variance of the subject-specific predicted ratings on trial 1 for GS3 (i.e. T=0) 4.428 0.943 <.0001 
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2
(4)σ  Variance of the subject-specific predicted ratings on trial 4 for GS3 (i.e. T=0) 3.193 0.714 <.0001 
2
εσ  Variance of the error term 4.524 0.240 <.0001 
R2 Proportion of explained variance 61.6%   
Regression model predicting fear of movement-related pain 
Coefficient Description Estimate SE p-value 
(1)µ  Predicted rating at trial 1 for GS3 (i.e. T=0) for HC (i.e. 0G = ), and an average random intercept 
value (i.e. 0iθ = ) 
1.681 0.392 <.0001 
(1)
LIN
β  Average change in the predicted rating at trial 1 for GSk compared with GSk-1 for HC (i.e. 0G =
). 
-0.314 0.055 <.0001 
(1)
QUAD
β  Half of the expected change in the slope of the linear trend for trial 1 for GSk compared with 
stimulus GSk-1 for HC (i.e. 0G = ). -0.007 0.031 0.821 
(1)
G
β  Average difference in the predicted rating at trial 1 for GS3 (i.e. T=0) for HC vs. FM 0.644 0.555 0.246 
(1)
LINxG
β  Difference in the slope of the linear trend at trial 1 for HC vs. FM -0.021 0.077 0.781 
(1)
QUADxG
β  Half of the difference in the expected change in the slope of the linear trend at trial 1 for GSk 
compared with GSk-1 for HC vs. FM 
0.077 0.045 0.084 
(4)µ  Predicted rating at trial 4 for GS3 (i.e. T=0) for HC (i.e. 0G = ), and an average random intercept 
value (i.e. 0iθ = ) 
0.594 0.330 0.077 
(4)
LIN
β  Average change in the predicted rating at trial 4 for GSk compared with GSk-1 for HC (i.e. 0G = ) -0.325 0.055 <.0001 
(4)
QUAD
β  Half of the expected change in the slope of the linear trend at trial 4 for GSk compared with GSk-1 
for HC (i.e. 0G = ) 0.093 0.031 0.003 
(4)
G
β  Average difference in the predicted rating at trial 4 for GS3 (i.e. T=0) for HC vs. FM 0.871 0.466 0.062 
(4)
LINxG
β  Difference in the slope of the linear trend at trial 4 for HC vs. FM -0.051 0.077 0.507 
(4)
QUADxGβ  Half of the difference in the expected change in the slope of the linear trend at trial 4 for 
stimulus GSk compared with Gk-1 HC vs. FM 
0.065 0.045 0.142 
2
(1)σ  Variance of the subject-specific predicted ratings on trial 1 for GS3 (i.e. T=0) 3.784 0.769 <.0001 
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2
(4)σ  Variance of the subject-specific predicted ratings on trial 4 for GS3 (i.e. T=0) 2.426 0.517 <.0001 
2
εσ  Variance of the error term 2.497 0.132 <.0001 
R2 Proportion of explained variance 65.2%   
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Multilevel regression model predicting retrospective fear of movement-related pain ratings for 
CS+ versus CS- during the acquisition and transfer-of-acquisition phases for subjects of the 
control group (HC) versus fibromyalgia (FM) group 
To describe the model we assume that ijklY  represents the rating of fear of movement-related pain of 
person i (i=1,..,60) of group l (l=HC, FM) for stimulus k (k=CS-, CS+) after block j of the acquisition 
or transfer-of-acquisition phase (j=A1, A2, A3, T1). It is assumed that observed ratings change linearly 
at the subsequent blocks. In particular, the linear trend variable Tj (which equals 0, 1, 2, 3 for blocks 
j=A1, A2, A3, T1) is used to model a linear trend of the observed rating in the subsequent blocks. 
Furthermore, the variable Gl equals 0 for HC and 1 for FM. 
The following multilevel regression model is used: 
( ) ( ) ( ) ( )k k k k
ijkl i T j G l TxG j l ijklY T G T Gθ µ β β β ε= + + + + +  
The model includes specific regression coefficients for each of the stimuli (k=CS-, CS+). Furthermore, 
the model includes a subject-specific  random intercept 2~ (0, )i N θθ σ  to model subject differences in 
the observed ratings after block A1, and an error term 2~ (0, )ijkl N εε σ  to model unexplained noise in 
the data. 
The parameters of the model should be interpreted as follows: 
( )kµ = Predicted intercept of the linear trend (i.e. at T=0) of stimulus type k for subjects of HC with  
an average random intercept value. 
( )k
Tβ = Slope of the linear trend of stimulus type k for subjects of HC. 
( )k
Gβ =Increase in the intercept of the linear trend (i.e. at T=0) of stimulus type k for FM compared to 
HC. 
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( )k
TxGβ = Increase in the slope of the linear trend of stimulus type for FM compared to HC.  
2
θσ = Variance of the subject-specific predicted ratings at block A1 (i.e. T=0). 
2
εσ = Variance of the error term. 
 
Multilevel regression model predicting pain-US expectancy and fear of movement-related pain 
ratings for CS+ versus CS- during the transfer-of-acquisition phase for subjects of the control 
(HC) group versus fibromyalgia (FM) group 
To describe the model we assume that ijklY  represents the rating (i.e. fear of movement-related pain or 
pain-US expectancy) of person i (i=1,..,60) of group l (l=HC, FM) for stimulus k (k=CS-, CS+) after 
trial j of the transfer phase (j=T1, T2, T3, T4). It is assumed that observed ratings change linearly at the 
subsequent trials. In particular, the linear trend variable Tj (which equals 0, 1, 2, 3 for trials j=T1, T2, 
T3, T4) is used to model a linear trend of the observed rating in the subsequent trials. Furthermore, the 
variable Gl equals 0 for subjects of HC and 1 for subjects of FM. 
The following multilevel regression model is used: 
( ) ( ) ( ) ( ) ( )k k k k k
ijkl i T j G l TxG j l ijklY T G T Gθ µ β β β ε= + + + + +  
The model includes specific regression coefficients for each of the stimuli (k=CS-, CS+). Furthermore, 
the model includes subject-specific  random intercepts  ( )kiθ  for each of the stimuli (k=CS-, CS+) to 
model subject differences in the observed ratings after trial T1, and an error term 2~ (0, )ijkl N εε σ  to 
model unexplained noise in the data. It is assumed that the random intercepts (!!(!"!), !!(!"!)) have a 
multivariate normal distribution with mean (0,0) and a variance-covariance matrix that is estimated 
from the data. 
The parameters of the model should be interpreted as follows: 
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( )kµ = Predicted intercept of the linear trend (i.e. at T=0) of stimulus type k for subjects of HC with  
an average random intercept value. 
( )k
Tβ = Slope of the linear trend of stimulus type k for subjects of HC. 
( )k
Gβ =Increase in the intercept of the linear trend (i.e. at T=0) of stimulus type k for FM compared to 
HC. 
( )k
TxGβ = Increase in the slope of the linear trend of stimulus type k for FM compared to HC.  
2
( )kσ = Variance of the subject-specific predicted ratings at T1 (i.e. T=0) for stimulus type k. 
2
εσ = Variance of the error term. 
 
Multilevel regression model predicting the generalization and extinction of generalization of 
pain-US expectancy and fear of movement-related pain ratings for subjects of the control group 
(HC) versus fibromyalgia (FM) group 
To describe the model we assume that ijklY represents the rating (i.e. fear of movement-related pain or 
pain-US expectancy) of person i (i=1,..,60) on trial j (j=trial 1, trial 4) of group l (l= HC, FM) for 
conditioned or generalization stimulus k (k=CS+, GS1, GS2, GS3, GS4, GS5, CS-). It is assumed that, 
for each trial, observed ratings change quadratically in the subsequent stimuli approaching from CS+ 
and CS-. The centered linear trend variable Tk (which equals -3, -2, -1, 0, 1, 2, 3 for stimuli k=CS+, 
GS1, GS2, GS3, GS4, GS5, CS-) is used to capture a linear component in the observed rating for the 
set of conditioned and generalization stimuli modeling the expected generalization gradient. Likewise, 
the quadratic component is modelled by including the quadratic variable 2( )kT  in the model. The 
variable Gl equals 0 for subjects of HC and 1 for subjects of FM. To investigate whether the strength 
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of the linear (quadratic) component differs for HC versus FM, we include an interaction between G 
and the linear (quadratric) trend variable.  
In particular, the following multilevel regression model is used: 
( ) ( ) ( ) ( ) 2 ( ) ( ) ( ) 2( ) ( )
i LINxG QUADxG
j j j j j j j
ijkl LIN k QUAD k G l k l k l ijklY T T G T G T Gµ θ β β β β β ε= + + + + + + +  
The model includes a subject-specific  random intercept ( )
i
jθ  to model subject differences in the 
reported ratings for stimulus GS3 at trial j, and an error term 2~ (0, )ijkl N εε σ  to model unexplained 
noise in the data. It is assumed that ( 1) ( 4)( , )trial triali iθ θ has a bivariate distribution with mean (0,0) and a 
covariance matrix that is estimated from the data. 
The parameters of the model should be interpreted as follows: 
( )jµ = Predicted rating at trial j for GS3 (i.e. T=0) for subjects of HC (i.e. 0G = ), and an average 
random intercept value (i.e. ( ) 0jiθ = ). 
( )
LIN
jβ = Average change in the predicted rating for GS k at trial j compared with GS k-1 for subjects of 
HC (i.e. 0G = ). 
( )2*
QUAD
jβ = Expected change in the slope of the linear trend for GS k at trial j compared with GS k-1 for 
subjects of HC (i.e. 0G = ). 
( )j
Gβ = Average difference in the predicted rating for GS3 (i.e. T=0) at trial j for FM versus HC. 
( )j
LINxGβ = Interaction effect between the linear trend and the group variable. This effect represents the 
difference in the slope of the linear trend component for trial j for FM versus HC. 
( )2* jQUADxGβ = Difference in the expected change in the slope of the linear trend for trial j for GS k 
compared with GS k-1 for FM versus HC. 
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2
( )jσ = Variance of the subject-specific predicted ratings at trial j for GS3 (i.e. T=0). 
2
εσ = Variance of the error term. 
 
 
 
	
 
 
 
 
 
